Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 7.5% in January

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the recipient of a large growth in short interest in January. As of January 31st, there was short interest totalling 18,600 shares, a growth of 7.5% from the January 15th total of 17,300 shares. Currently, 0.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 11,200 shares, the short-interest ratio is currently 1.7 days.

Armata Pharmaceuticals Trading Down 1.0 %

NYSEAMERICAN:ARMP traded down $0.02 during trading hours on Tuesday, hitting $1.93. 27,829 shares of the stock were exchanged, compared to its average volume of 9,878. Armata Pharmaceuticals has a 52-week low of $1.80 and a 52-week high of $4.48. The firm has a market cap of $69.83 million, a P/E ratio of -1.18 and a beta of 0.87.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Armata Pharmaceuticals in a research report on Thursday, December 19th.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.